Key facts
- ShiraTronics, Inc. issued a correction.
- The correction pertains to a news release dated 02-Jun-2026.
- The original news release was about the RELIEV-CM2 pivotal trial for chronic migraine.
ShiraTronics, Inc. has issued a correction to a previously released news statement. The original statement, dated June 2, 2026, concerned the completion of enrollment in the RELIEV-CM2 pivotal trial. This trial focuses on implantable extracranial neuromodulation systems (IENs) for the treatment of chronic migraine. The company has advised that changes have been made to the original release.